Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer

Breast Cancer Research

Volumn 9, Issue 3, 2007, Pages

  Berishaj, Marjan ^a   Gao, Sizhi Paul ^a   Ahmed, Simi ^b   Leslie, Kenneth ^a   Al Ahmadie, Hikmat ^a   Gerald, William L ^a   Bornmann, William ^c   Bromberg, Jacqueline F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN 130, HUMAN; PHOSPHOTYROSINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; JANUS KINASES; PHOSPHOTYROSINE; STAT3 TRANSCRIPTION FACTOR;

EID: 34548549283     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1680     Document Type: Article

References (47)

1. Clevenger CV: Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004, 165:1449-1460. 1618660 15509516
2. Yu H Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105. 14964307
3. Darnell JE Jr: STATs and gene regulation. Science 1997, 277:1630-1635. 10.1126/science.277.5332.1630 9287210
4. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142. 150969 11994401 10.1172/JCI200215617
5. Leslie K Lang C Devgan G Azare J Berishaj M Gerald W Kim YB Paz K Darnell JE Albanese C: Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 2006, 66:2544-2552. 10.1158/ 0008-5472.CAN-05-2203 16510571
6. Gritsko T Williams A Turkson J Kaneko S Bowman T Huang M Nam S Eweis I Diaz N Sullivan D: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006, 12:11-19. 10.1158/ 1078-0432.CCR-04-1752 16397018
7. Diaz N Minton S Cox C Bowman T Gritsko T Garcia R Eweis I Wloch M Livingston S Seijo E: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006, 12:20-28. 10.1158/1078-0432.CCR-04-1749 16397019
8. Lo HW Hsu SC Ali-Seyed M Gunduz M Xia W Wei Y Bartholomeusz G Shih JY Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589. 10.1016/j.ccr.2005.05.007 15950906
9. Vultur A Cao J Arulanandam R Turkson J Jove R Greer P Craig A Elliott B Raptis L: Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004, 23:2600-2616. 10.1038/ sj.onc.1207378 15007380
10. Turkson J Kim JS Zhang S Yuan J Huang M Glenn M Haura E Sebti S Hamilton AD Jove R: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004, 3:261-269. 15026546
11. Dolled-Filhart M Camp RL Kowalski DP Smith BL Rimm DL: Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis: Clin Cancer Res 2003, 9:594-600. 12576423
12. Li L Shaw PE: Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem 2002, 277:17397-17405. 10.1074/jbc.M109962200 11859072
13. Garcia R Bowman TL Niu G Yu H Minton S Muro-Cacho CA Cox CE Falcone R Fairclough R Parsons S: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513. 10.1038/sj.onc.1204349 11420660
14. Garcia R Yu CL Hudnall A Catlett R Nelson KL Smithgall T Fujita DJ Ethier SP Jove R: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997, 8:1267-1276. 9419415
15. Watson CJ Miller WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 1995, 71:840-844. 7710952
16. Dechow TN Pedranzini L Leitch A Leslie K Gerald WL Linkov I Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 2004, 101:10602-10607. 489981 15249664 10.1073/pnas.0404100101
17. Cotarla I Ren S Zhang Y Gehan E Singh B Furth PA: Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004, 108:665-671. 10.1002/ijc.11619 14696092
18. Kotha A Sekharam M Cilenti L Siddiquee K Khaled A Zervos AS Carter B Turkson J Jove R: Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 2006, 5:621-629. 10.1158/1535-7163.MCT-05-0268 16546976
19. Selander KS Li L Watson L Merrell M Dahmen H Heinrich PC Muller-Newen G Harris KW: Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 2004, 64:6924-6933. 10.1158/0008-5472.CAN-03-2516 15466183
20. Alvarez JV Febbo PG Ramaswamy S Loda M Richardson A Frank DA: Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005, 65:5054-5062. 10.1158/0008-5472.CAN-04-4281 15958548
21. Ling X Arlinghaus RB: Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005, 65:2532-2536. 10.1158/0008-5472.CAN-04-2425 15805244
22. Guo W Pylayeva Y Pepe A Yoshioka T Muller WJ Inghirami G Giancotti FG: Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006, 126:489-502. 10.1016/j.cell.2006.05.047 16901783
23. Berclaz G Altermatt HJ Rohrbach V Siragusa A Dreher E Smith PD: EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 2001, 19:1155-1160. 11713584
24. Amorino GP Hamilton VM Valerie K Dent P Lammering G Schmidt-Ullrich RK: Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 2002, 13:2233-2244. 117308 12134064 10.1091/mbc.01-12-0572
25. Grant SL Hammacher A Douglas AM Goss GA Mansfield RK Heath JK Begley CG: An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 2002, 21:460-474. 10.1038/sj.onc.1205100 11821958
26. Knupfer H Preiss R: Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007, 102:129-135. 10.1007/ s10549-006-9328-3 16927176
27. KishimotoFT: Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005, 23:1-21. 10.1146/ annurev.immunol.23.021704.115806 15771564
28. Debnath J Muthuswamy SK Brugge JS: Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268. 10.1016/ S1046-2023(03)00032-X 12798140
29. Minn AJ Gupta GP Siegel PM Bos PD Shu W Giri DD Viale A Olshen AB Gerald WL Massague J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 1283098 16049480 10.1038/nature03799
30. Doane AS Danso M Lal P Donaton M Zhang L Hudis C Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008. 10.1038/sj.onc.1209415 16491124
31. Rincon M Broadwater G Harris L Crocker A Weaver D Dressler L Berry D Sutton L Michaelson R Messino M: Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: Results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 2006, 100:301-308. 10.1007/s10549-006-9251-7 16773437
32. Sartor CI Dziubinski ML Yu CL Jove R Ethier SP: Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res 1997, 57:978-987. 9041204
33. Ferrajoli A FadeAl S Ravandi F Estrov Z: The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006, 6:671-679. 10.2174/156800906779010227 17168672
34. Levitzki A Mishani E: Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 2006, 75:93-109. 10.1146/ annurev.biochem.75.103004.142657 16756486
35. Thompson JE: JAK protein kinase inhibitors Drug News Perspect 2005, 18:305-310. 10.1358/dnp.2005.18.5.904198 16193102
36. Pedranzini L Dechow T Berishaj M Comenzo R Zhou P Azare J Bornmann W Bromberg J: Pyridone 6, a pan-janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006, 66:9714-9721. 10.1158/0008-5472.CAN-05-4280 17018630
37. Thompson JE Cubbon RM Cummings RT Wicker LS Frankshun R Cunningham BR Cameron PM Meinke PT Liverton N Weng Y: Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002, 12:1219-1223. 10.1016/S0960-894X(02)00106-3 11934592
38. Nam S Kim D Cheng JQ Zhang S Lee JH Buettner R Mirosevich J Lee FY Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189. 10.1158/ 0008-5472.CAN-05-1731 16230377
39. Song L Morris M Bagui T Lee FY Jove R Haura EB: Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006, 66:5542-5548. 10.1158/0008-5472.CAN-05-4620 16740687
40. Moasser MM Basso A Averbuch SD Rosen N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001, 61:7184-7188. 11585753
41. Minn AJ Kang Y Serganova I Gupta GP Giri DD Doubrovin M Ponomarev V Gerald WL Blasberg R Massague J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55. 539194 15630443 10.1172/JCI200522320
42. LAvy DE Inghirami G: STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006, 103:10151-10152. 1502425 16801534 10.1073/pnas.0604042103
43. Xi S Gooding WE Grandis JR: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene 2005, 24:970-979. 10.1038/sj.onc.1208316 15592503
44. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004, 8:409-422. 10.1517/14728222.8.5.409 15469392
45. Turkson J Zhang S Mora LB Burns A Sebti S Jove R: A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005, 280:32979-32988. 10.1074/jbc.M502694200 16046414
46. Alexander WS Hilton DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004, 22:503-529. 10.1146/annurev.immunol.22.091003.090312 15032587
47. Evans MK Yu CR Lohani A Mahdi RM Liu X Trzeciak AR Egwuagu CE: Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 2007, 26:1941-1948. 10.1038/sj.onc.1209993 17001312